EVALUATION OF ADHERENCE TO BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH INFLAMMATORY ARTHRITIS

被引：0
|
作者：
Lim, Y. C. [1 ]
Teo, W. G. [2 ]
Eng, M. N. [1 ]
Cheen, H. M. [1 ]
Tay, X. Y. [1 ]
Yeo, S. I. [3 ]
Lim, T. G. [1 ]
机构：
[1] Singapore Gen Hosp, Pharm, Singapore, Singapore
[2] Natl Heart Ctr Singapore, Pharm, Singapore, Singapore
[3] Singapore Gen Hosp, Rheumatol & Immunol, Singapore, Singapore
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
RHEUMATOID-ARTHRITIS;
D O I：
10.1136/annrheumdis-2018-eular.2183
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0748-HP
引用
收藏
页码：1800 / 1800
页数：1
相关论文
共 50 条
  • [1] ADHERENCE TO BIOLOGIC AND CONVENTIONAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Mishra, P.
    VALUE IN HEALTH, 2018, 21 : S198 - S198
  • [2] SARCOPENIA IN PATIENTS WITH RHEUMATOID ARTHRITIS ON THE TREATMENT WITH BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
    Hasegawa, E.
    Ito, S.
    Kurosawa, Y.
    Taniguchi, S.
    Kobayashi, D.
    Abe, A.
    Otani, H.
    Nakazono, K.
    Murasawa, A.
    Narita, I.
    Ishikawa, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 985 - 985
  • [3] Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Choy, Ernest
    Aletaha, Daniel
    Behrens, Frank
    Finckh, Axel
    Gomez-Reino, Juan
    Gottenberg, Jacques-Eric
    Schuch, Florian
    Rubbert-Roth, Andrea
    RHEUMATOLOGY, 2017, 56 (05) : 689 - 697
  • [4] Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis
    Min, Hong Ki
    Kim, Se Hee
    Kim, Hae-Rim
    Lee, Sang-Heon
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [5] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Pundole, Xerxes
    Zamora, Natalia V.
    Siddhanamatha, Harish
    Lin, Heather
    Tayar, Jean
    Hong, Leung Cheuk
    Li, Liang
    Suarez-Almazor, Maria E.
    CLINICAL RHEUMATOLOGY, 2020, 39 (03) : 787 - 794
  • [6] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Xerxes Pundole
    Natalia V. Zamora
    Harish Siddhanamatha
    Heather Lin
    Jean Tayar
    Leung Cheuk Hong
    Liang Li
    Maria E. Suarez-Almazor
    Clinical Rheumatology, 2020, 39 : 787 - 794
  • [7] SECONDARY SARCOPENIA IN RHEUMATOID ARTHRITIS PATIENTS TREATED BY BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
    Hasegawa, Eriko
    Ito, Satoshi
    Kurosawa, Yoichi
    Kobayashi, Daisuke
    Abe, Asami
    Otani, Hiroshi
    Nakazono, Kiyoshi
    Murasawa, Akira
    Narita, Ichiei
    Ishikawa, Hajime
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1622 - 1622
  • [8] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Monchablon, Clelia
    Gonde, Henri
    Pouplin, Sophie
    Varin, Remi
    Vittecoq, Olivier
    Lequerre, Thierry
    CLINICAL RHEUMATOLOGY, 2020, 39 (01) : 207 - 216
  • [9] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Clélia Monchablon
    Henri Gondé
    Sophie Pouplin
    Rémi Varin
    Olivier Vittecoq
    Thierry Lequerré
    Clinical Rheumatology, 2020, 39 : 207 - 216
  • [10] Longitudinal adherence trajectories to biologic disease modifying anti-rheumatic drugs in Tuscany, Italy
    Giometto, Sabrina
    Convertino, Irma
    Tuccori, Marco
    Gini, Rosa
    Cazzato, Massimiliano
    Valdiserra, Giulia
    Cappello, Emiliano
    Ferraro, Sara
    Tillati, Silvia
    Fornili, Marco
    Bartolini, Claudia
    Paoletti, Olga
    Turchetti, Giuseppe
    Trieste, Leopoldo
    Lorenzoni, Valentina
    Blandizzi, Corrado
    Mosca, Marta
    Lucenteforte, Ersilia
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 31 - 32
12345